title: Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study.
abstract: The administration of human serum albumin has been reported to prevent severe ovarian hyperstimulation syndrome (OHSS) while undergoing ovarian stimulation protocols for in-vitro fertilization (IVF). This prospective, randomized study investigated the effectiveness of a single dose of human serum albumin (20 g) administered i.v. immediately after oocyte retrieval. Women enrolled in the IVF programme were treated with long gonadotrophin-releasing hormone agonist, triptorelin, and an individually-adjusted human menopausal gonadotrophin protocol. The criteria for inclusion in the study were young age, non-obesity, oestradiol concentration > 9200 pmol/l on the day of human chorionic gonadotrophin administration and > 20 follicles > 14 mm diameter as observed by transvaginal sonography. The treatment group (n = 22) received albumin while the control group (n = 18) did not. Patients were followed-up using ultrasound every 3 days. There was a significantly higher number of severe OHSS cases in the control group (n = 4) than in the treatment group (n = 0) (P = 0.035). Where the data base was restricted to patients with an oestradiol concentration > 15,000 pmol/l, the difference between control and treatment groups was highly significant (P = 0.008). These findings support the use of i.v. albumin in preventing severe OHSS during IVF treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Central Emek Hospital, Afula, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Shalev
authors.forename: Y
authors.initials: Y
authors.lastname: Giladi
authors.forename: M
authors.initials: M
authors.lastname: Matilsky
authors.forename: M
authors.initials: M
authors.lastname: Ben-Ami
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D016471:Ovarian Hyperstimulation Syndrome / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000627:therapeutic use*
chemical_list: D012709:Serum Albumin